Michael D. Schwartz

Michael D. Schwartz

Auto-generated profile, based on publicly available information

Michael D. Schwartz

A Center for Neuroscience , SRI International , Menlo Park , CA , USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2018 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
MSMichael D. Schwartz
Michael D. Schwartz
JCJuan J. Canales
Juan J. Canales
RZRiccardo Zucchi
Riccardo Zucchi
SEStefano Espinoza
Stefano Espinoza
ISIlya Sukhanov
Ilya Sukhanov
Raul R GainetdinovRaul R Gainetdinov
Raul R Gainetdinov
Introduction: The trace amines, endogenous amines closely related to the biogenic amine neurotransmitters, have been known to exert physiological and neurological effects for decades. The recent identification of a trace amine-sensitive G protein-coupled receptor, trace amine-associated receptor 1 (TAAR1), and subsequent development of TAAR1-selective small-molecule ligands, has renewed research into the therapeutic possibilities of trace amine signaling. Areas covered: Recent efforts in elucidating the neuropharmacology of TAAR1, particularly in neuropsychiatric and neurodegenerative disease, addiction, and regulation of arousal state, will be discussed. Focused application of TAAR1 mutants, synthetic TAAR1 ligands, and endogenous biomolecules such as 3-iodothyronamine (T1AM) has yielded a basic functional portrait for TAAR1, despite a complex biochemistry and pharmacology. The close functional relationship between TAAR1 and dopaminergic signaling is likely to underlie many of its CNS effects. However, TAAR1’s influences on serotonin and glutamate neurotransmission will also be highlighted. Expert opinion: TAAR1 holds great promise as a therapeutic target for mental illness, addiction, and sleep disorders. A combination of preclinical and translationally driven studies has solidified TAAR1 as a key node in the regulation of dopaminergic signaling. Continued focus on the mechanisms underlying TAAR1’s regulation of serotonin and glutamate signaling, as well as dopamine, will yield further disease-relevant insights.

21 May 2013 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
WBWilliam A. Bauman
William A. Bauman
ASAnn M. Spungen
Ann M. Spungen
JCJoseph F. Collins
Joseph F. Collins
DRDennis W. Raisch
Dennis W. Raisch
CHChester Ho
Chester Ho
RTRose C. Trincher
Rose C. Trincher
Chinese translation Anabolic steroids have been reported to improve wound healing. To determine whether oxandrolone increases the percentage of target pressure ulcers (TPUs) that heal compared with placebo and whether healed ulcers remain closed 8 weeks after treatment. Parallel-group, placebo-controlled, randomized trial conducted from 1 August 2005 to 30 November 2008. Patients, clinical care providers, study personnel, and statisticians were blinded to treatment assignment. (ClinicalTrials.gov: NCT00101361) 16 inpatient spinal cord injury (SCI) services at Veterans Affairs medical centers. 1900 prescreened, 779 screened, and 212 randomly assigned inpatients with SCI and stage III or IV TPUs. Oxandrolone, 20 mg/d (n = 108), or placebo (n = 104) until the TPU healed or 24 weeks. The primary outcome was healed TPUs. The secondary outcome was the percentage of TPUs that remained healed at 8-week follow-up. 24.1% (95% CI, 16.0% to 32.1%) of TPUs in oxandrolone recipients and 29.8% (CI, 21.0% to 38.6%) in placebo recipients healed (difference, −5.7 percentage points [CI, −17.5 to 6.8 percentage points]; P = 0.40). At 8-week follow-up, 16.7% (CI, 9.6% to 23.7%) of oxandrolone recipients and 15.4% (CI, 8.5% to 22.3%) of placebo recipients retained a healed TPU (difference, 1.3 percentage points [CI, −8.8 to 11.2 percentage points]; P = 0.70). No serious adverse events were related to oxandrolone. Liver enzyme levels were elevated in 32.4% (CI, 23.6% to 41.2%) of oxandrolone recipients and 2.9% (CI, 0.0% to 6.1%) of placebo recipients (P < 0.001). Selection of severe wounds may have reduced treatment response. Approximately one third of patients did not complete the study in the treatment and placebo groups. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between the groups. Oxandrolone showed no benefit over placebo for improving healing or the percentage of TPUs that remained closed after 8 weeks of treatment. U.S. Department of Veterans Affairs.

1 December 2007 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
MSMichael D Schwartz
Michael D Schwartz
RGRobert J Geller
Robert J Geller
Lamotrigine is a commonly prescribed anticonvulsant medication. It is an infrequently reported agent of intentional acute ingestion to poison centers. The spectra of clinical effects of lamotrigine in acute overdose are not well established. We report a case of acute ingestion of lamotrigine and ethanol that resulted in coma requiring ventilatory support, paradoxic seizure activity, and mild rhabdomyolysis.

1 January 2016 in eneuro
Verified
Journal Article
Open access
PDF file
MSMichael D. Schwartz
Michael D. Schwartz
ANAlexander T. Nguyen
Alexander T. Nguyen
DWDeepti R. Warrier
Deepti R. Warrier
JPJeremiah B. Palmerston
Jeremiah B. Palmerston
ATAlexia M. Thomas
Alexia M. Thomas
TKThomas Kilduff
Thomas Kilduff
Hypocretin 1 and 2 (Hcrts, also known as orexin A and B), excitatory neuropeptides synthesized in cells located in the tuberal hypothalamus, play a central role in the control of arousal. Hcrt inputs to the locus coeruleus norepinephrine (LC NE) system and the posterior hypothalamic histaminergic tuberomammillary nuclei (TMN HA) are important efferent pathways for Hcrt-induced wakefulness. The LC expresses Hcrt receptor 1 (HcrtR1) whereas HcrtR2 is found in the TMN. Although the dual Hcrt/orexin receptor antagonist almorexant (ALM) decreases wakefulness and increases NREM and REM sleep time, the neural circuitry that mediates these effects is currently unknown. To test the hypothesis that ALM induces sleep by selectively disfacilitating subcortical wake-promoting populations, we ablated LC NE neurons (LCx) or TMN HA neurons (TMNx) in rats using cell-type specific saporin conjugates and evaluated sleep/wake following treatment with ALM and the GABAA receptor modulator zolpidem (ZOL). Both LCx and TMNx attenuated the promotion of REM sleep by ALM without affecting ALM-mediated increases in NREM sleep. Thus, eliminating either HcrtR1 signaling in the LC or HcrtR2 signaling in the TMN yields similar effects on ALM-induced REM sleep without affecting NREM sleep time. In contrast, neither lesion altered ZOL efficacy on any measure of sleep-wake regulation. These results contrast with those of a previous study in which ablation of basal forebrain cholinergic neurons attenuated ALM-induced increases in NREM sleep time without affecting REM sleep, indicating that Hcrt neurotransmission influences distinct aspects of NREM and REM sleep at different locations in the sleep-wake regulatory network. Significance Statement: The hypocretin/orexin (Hcrt) system powerfully regulates arousal in part by excitatory projections to wake-promoting cell groups in the posterior hypothalamus and brainstem. Cell-type specific ablations of the locus coeruleus norepinephrine (LC NE) neurons or the tuberomammillary histamine (TMN HA) neurons decreased the hypnotic efficacy of the dual Hcrt receptor antagonist Almorexant, while having no effect on sleep promotion by the GABA receptor modulator zolpidem. Lesioning the LC or TMN attenuated Almorexant-induced REM sleep without affecting NREM sleep time. Lesions exerted similar effects independently of the Hcrt receptor type expressed in each region, suggesting that the site of action, not just the specific receptor or receptors targeted, is a key determinant of how Hcrt receptor antagonism facilitates sleep.

1 June 2005 in American Journal of Industrial Medicine
Verified
Journal Article
Closed access
PDF file
MSMichael D. Schwartz
Michael D. Schwartz
AOAndrew O. Obamwonyi
Andrew O. Obamwonyi
JTJerry D. Thomas
Jerry D. Thomas
JMJoel F. Moorhead
Joel F. Moorhead
BMBrent W. Morgan
Brent W. Morgan